Want to successfully climb the ladder? Plan your own route, experts advise, because career paths in clinical research aren’t often crystal clear.
The FDA has exceeded it own expectations for how many inspections it could complete in recent pandemic conditions.
Sites need to have a voice from the outset when working with vendors and sponsors to bring new or upgraded technology to bear on clinical trials.
Expect FDA to maintain use of “hybrid” inspection tools and tactics, agency official says.
ACRP talked to Chris Komelasky, CEO & Founder of Site Bridge Research, about what steps need to be taken to broaden clinical research into underserved and minority populations.